Endogenous Candida endophthalmitis

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 4, 2006, Pages 675-685

  Sallam, Ahmed ^a   Lynn, William ^b   McCluskey, Peter ^c   Lightman, Sue ^a  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b EALING HOSPITAL   (United Kingdom)

^c LIVERPOOL HOSPITAL   (Australia)

Author keywords

Amphotericin B; Candida; Caspofungin; Chorioretinitis; Endogenous endophthalmitis; Fluconazole; Intravitreal therapy; Vitrectomy; Voriconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; DEOXYCHOLATE SODIUM; DEXAMETHASONE; FLOXURIDINE PHOSPHATE; FLUCONAZOLE; FLUCYTOSINE; FLUOROURACIL; ITRACONAZOLE; KETOCONAZOLE; POSACONAZOLE; STEROID; VORICONAZOLE;

BLURRED VISION; CANDIDA; CANDIDIASIS; CHORIORETINITIS; CLINICAL FEATURE; CLINICAL TRIAL; COLOR VISION DEFECT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISTRIBUTION; DRUG PENETRATION; EARLY DIAGNOSIS; ENDOPHTHALMITIS; EYE INFECTION; FEVER; HUMAN; HYPOKALEMIA; HYPOTENSION; LIVER DYSFUNCTION; NEPHROTOXICITY; NONHUMAN; PATIENT CARE; PHOTOSENSITIVITY; PROGNOSIS; RASH; RETINA; REVIEW; UNSPECIFIED SIDE EFFECT; UVEA; VISUAL DISORDER; VISUAL IMPAIRMENT;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; ENDOPHTHALMITIS; EYE INFECTIONS, FUNGAL; HUMANS;

EID: 33749536415     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.4.675     Document Type: Review

References (103)

1. Chen YC, Chang SC, Luh KT et al. Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. J. Antimicrob. Chemother. 52(1), 71-77 (2003).
2. Kibbler CC, Seaton S, Barnes RA et al. Management and outcome of bloodstream infections due to Candida species in England and Wales. J. Hosp. Infect. 54(1), 18-24 (2003).
3. Pfaller MA, Diekema DJ, Messer SA et al. Activities of fluconazole and variconazole against 1,586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion and Etest methods: report from the ARTEMIS global antifungal susceptibility program, 2001. J. Clin. Microbiol. 41(4), 1440-1446 (2003).
4. Donahue SP, Greven CM, Zuravleff JJ et al. Intraocular candidiasis in patients with candidemia. Clinical implications derived from a prospective multicenter study. Ophthalmology 101(7), 1302-1309 (1994).
5. McDonnel PJ, McDonnel JM, Brown RH et al. Ocular involvement in patients with fungal infections. Ophthalmology 92(5), 706-709 (1985).
6. Brooks RG. Prospective study of Candida endophthalmitis in hospitalized patients with candidemia. Arch. Intern. Med. 149(10), 2226-2228 (1989).
7. Bross J, Talbot GH, Maislin G et al. Risk factors for nosocomial candidemia: a case-control study in adults without leukemia. Am. J. Med. 87(6), 614-620 (1989).
8. Krishna R, Amuh D, Lowder CY et al. Should all patients with candidemia have an ophthalmic examination to rule out ocular candidiasis? Eye 14(Pt 1), 30-34 (2000).
9. Griffin JR, Pettit TH, Fishman LS et al. Blood-borne Candida endophthalmitis. A clinical and pathologic study of 21 cases. Arch. Ophthalmol. 89(6), 450-456 (1973).
10. Pappas PG, Rex JH, Lee J et al.; NIAID Mycoses Study Group. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis. 37, 634-643 (2003).
11. Feman SS, Nichols JC, Chung SM et al. Endophthalmitis in patients with disseminated fungal disease. Trans. Am. Ophthalmol Soc. 100, 67-71 (2002).
12. Kostick DA, Foster RE, Lowder CY et al. Endogenous endoplithalmitis caused by Candida albicans in a healthy woman. Am. J. Ophthalmol. 113(5), 593-595 (1992).
13. Marangon FB, Miller D, Giaconi JA et al. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am. J. Ophthalmol. 37(5), 820-825 (2004).
14. Sarria JC, Bradley JC, Habash R et al. Candida glabrata endophthalmitis treated successfully with caspofungin. Clin. Infect. Dis. 40(5), E46-F48 (2005).
15. Breit SM, Hariprasad SM, Mieler WF et al. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am. J. Ophthalmol. 139(1), 135-140 (2005).
16. Takebayashi H, Mizota A, Tanaka M. Relation between stage of endogenous fungal endophthalmitis and prognosis. Graefes Arch. Clin. Exp. Ophthalmol. 6, 1-5 (2005).
17. Rao NA, Hidayat A. A comparative clinicopathologic study of endogenous mycotic endophthalmitis: variations in clinical and histopathologic changes in candidiasis compared to aspergillosis. Am. J. Ophthalmol. 132(2), 244-251 (2001).
18. Essman TF, Flynn HW, Smiddy WE et al. Treatment outcomes in a 10-year study of fungal endophthalmitis. Ophthalmic. Surg. Lasers 28(3), 185-194 (1997).
19. Tanaka M, Kobayashi Y, Takebayashi H et al. Analysis of predisposing clinical and laboratory findings for the development of endogenous fungal endophthalmitis. A retrospective 12-year study of 79 eyes of 46 patients. Retina 21(6), 572-574 (2001).
20. Uzun O, Ascioglu S, Anaissie EJ et al. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin. Infect. Dis. 32(12), 1713-1717 (2001).
21. DiNubile MJ, Hille D, Sable CA et al. Invasive candidiasis in cancer patients: observations from a randomized clinical trial. J. Infect. 50(5), 443-449 (2005).
22. Tsai CC, Chen SJ, Chung YM et al. Postpartum endogenous Candida endophthalmitis. J. Formos Med. Assoc. 101(6), 432-436 (2002).
23. Sikic J, Vukojevic N, Katusic D et al. Bilateral endogenous Candida endophthalmitis after induced abortion. Croat. Med. J. 42(6), 676-678 (2001).
24. Jabs DA. Ocular manifestations of HIV infection. Trans. Am. Ophthalmol. Soc. 93, 623-683 (1995).
25. Miailhes P, Labetoulle M, Naas T et al. Unusual etiology of visual loss in an HIV-infected patient due to endogenous endophthalmitis. Clin. Microbiol. Infect. 70(11), 641-645 (2001).
26. Donahue SP, Hein E, Sinatra RB. Ocular involvement in children with candidemia. Am. J. Opthalmol. 135(6), 886-887 (2003).
27. Singh-Parikshak R, Bothun ED, Superstein R et al. Sequestration and late activation of lenticular Candida abscess in premature infants. Arch. Ophthalmol. 122(9), 1393-1395 (2004).
28. Manzoni P, Maestri A, Leonessa M et al. Fungal and bacterial sepsis and threshold ROP in preterm very low birth weight neonates. J. Perinatol. 26(1), 23-30 (2006).
29. Stone J, Chan-Ling T, Pe'er J et al. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 37(2), 290-299 (1996).
30. Binder MI, Chua J, Kaiser PK et al. Endogenous endophthalmitis: an 18-year review of culture-positive cases at a tertiary care center. Medicine (Baltimore) 82(2), 97-105 (2003).
31. Villafont H, Chaptal J, Rioux J et al. Mycoses retiniennes. A props de trois observations. Bull. Mem. Soc. Fr. Ophthalmol 77, 387 (1964).
32. Rodriguez-Adrian LJ, King RT, Tamayo-Derat LG et al. Retinal lesions as clues to disseminated bacterial and candidal infections: frequency, natural history, and etiology. Medicine (Baltimore) 82(3), 187-202 (2003).
33. Denning DW, Evans EG, Kibbler CC et al. Guidelines for the investigation of invasive fungal infections in haematological malignancy and solid organ transplantation. British Society for Medical Mycology. Eur. J. Clin. Microbiol. Infect. Dis. 16(6), 424-436 (1997).
34. Chowdhury T, Jalali S, Majji AB. Successful treatment of fungal retinitis and retinal vasculitis with oral itraconazole. Retina 22(6), 800-802 (2002).
35. Martinez-Vazquez C, Fernandez-Ulloa J, Bordon J et al. Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy. Clin. Infect. Dis. 27(5), 1130-1133 (1998).
36. Zhang YQ Wang WJ. Treatment outcomes after pars plana vitrectomy for endogenous endophthalmitis. Retina 25(6), 746-750 (2005).
37. Guan HJ, Lu H. Rapid pathogens diagnosis of infected keratitis and endophthalmitis using two steps polymerase chain reaction. Zhonghua Yan Ke Za Zhi 40(12), 819-823 (2004).
38. Jaeger EE, Carroll NM, Choudhury S et al. Rapid detection and identification of Candida, Aspergillus, and Fusarium species in ocular samples using nested PCR. J. Clin. Microbiol. 38(8), 2902-2908 (2000).
39. Hidalgo JA, Alangaden GJ, Eliott D et al. Fungal endophthalmitis diagnosis by detection of Candida albicans DNA in intraocular fluid by use of a species-specific polymerase chain reaction assay. J. Infect. Dis. 181(3), 1198-1202 (2000).
40. Okhravi N, Adamson P, Mant R et al. Polymerase chain reaction and restriction fragment length polymorphism mediated detection and speciation of Candida spp causing intraocular infection. Invest. Ophthalmol. Vis. Sci. 39, 859-866 (1998)
41. Schiedler V, Scott IU, Flynn HW Jr et al. Culture-proven endogenous endophthalmitis: clinical features and visual acuity outcomes. Am. J. Ophthalmol. 137(4), 725-731 (2004).
42. Pappas PG, Rex JH, Sobel JD et al. Infectious Diseases Society of America. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38(2), 161-189 (2004).
43. Lynn WA, Lightman S. The eye in systemic infection. Lancet 364(9443), 1439-1450 (2004).
44. Bolard J, Legrand P, Heitz F et al. One-sided action of amphotericin B on cholesterol-containing membranes is determined by its self-association in the medium. Biochemistry 30(23), 5707-5715 (1991).
45. Samra Z, Yardeni M, Peled N et al. Species distribution and antifungal susceptibility of Candida bloodstream isolates in a tertiary medical center in Israel. Eur. J. Clin. Microbiol. Infect. Dis. 24(9), 592-595 (2005).
46. Hovi L, Saarinen UM, Donner U et al. Opportunistic osteomyclitis in the jaws of children on immunosuppressive chemotherapy. J. Pediatr. Hematol. Oncol. 18(1), 90-94 (1996).
47. Canton E, Pcman J, Gobernado M et al. Patterns of amphotericin B killing kinetics against seven Candida species. Antimicrob. Agents Chemother. 48(7), 2477-2482 (2004).
48. Yang YL, Li SY, Cheng HH etal. The trend of susceptibilities to amphotericin B and fluconazole of Candida species from 1999 to 2002 in Taiwan. BMC Infect. Dis. 5, 99 (2005).
49. Capoor MR, Nair D, Deb M et al. Emergence of non-albicans Candida species and antifungal resistance in a tertiary care hospital. Jpn J. Infect. Dis. 58(6), 344-348 (2005).
50. O'Day DM, Head WS, Robinson RD et al. Intraocular penetration of systemically administered antiftingal agents. Curr. Eye Res. 4(2), 131-134 (1985).
51. Louie A, Liu W, Miller DA et al. Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans. Antimicrob. Agents Chemother. 43(12), 2831-2840 (1999).
52. Wegner B, Baer P, Gauer S et al. Caspofungin is less nephrotoxic than amphotericin B in vitro and predominantly damages distal renal tubular cells. Nephrol. Dial. Transplant. 20(10), 2071-2079 (2005).
53. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis. 27(3), 603-618 (1998).
54. Larabi M, Gulik A, Dedieu JP et al. New lipid formulation of amphotericin B: spectral and microscopic analysis. Biochim. Biophys. Acta 1664(2), 172-181 (2004).
55. Goldblum D, Rohrer K, Frueh BE et al. Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model. Antimicrob. Agents Chemother. 46(12), 3719-3723 (2002).
56. Diasio RB, Bennett JE, Myers CE. Mode of action of 5-fluorocytosine. Biochem. Pharmacol. 27(5), 703-707 (1978).
57. Walsh A, Haft DA, Miller MH et al. Ocular penetration of 5-fluorocytosine. Invest. Ophthalmol. Vis. Sci. 17(7), 691-694 (1978).
58. Oh KB, Yang HC, Matsuoka H et al. Combined effect of amphotericin B and flucytosine on hyphal growth of Candida albicans estimated at a single hypha level. J. Med. Vet. Mycol. 33(3), 191-195 (1995).
59. Kontoyiannis DP. Modulation of fluconazole sensitivity by the interaction of mitochondria and erg3p in Saccharomyces cerevisiae. J. Antimicrob. Chemother. 46(2), 191-197 (2000).
60. Fukuoka T, Johnston DA, Winslow CA et al. Genetic basis for differential activities of fluconazole and voriconazole against Candida Krusei. Antimicrob. Agents Chemother. 47(4), 1213-1219 (2003).
61. Debruyne D. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin. Pharmacokinet. 33(1), 52-77 (1997).
62. Goa KL, Barradell LB. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 50(4), 658-690 (1995).
63. Brockmeyer NH, Tillmann I, Mertins L et al. Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. Eur. J. Med. Res. 2(9), 377-383 (1997).
64. Kontoyiannis DP, Bodey GP, Mantzoros CS. Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis. Mycoses 44(5), 125-135 (2001).
65. Charlier C, Hart E, Lefort A et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J. Antimicrob. Chemother. 57(3), 384-410 (2006).
66. Odds FC. Fluconazole plus amphotericin B combinations are not contraindicated and may add benefit for the treatment of candidemia. Clin. Infect. Dis. 36(10), 1229-1231 (2003).
67. Rex JH, Pappas PG, Karchmer AW et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in non neutropenic subjects. Clin. Infect. Dis. 36(10), 1221-1228 (2003).
68. Safdar A, Chaturvedi V, Koll BS et al. Prospective, multicenter surveillance study of Candida glabrata: fluconazole and itraconazole susceptibility profiles in bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York City (Candida Susceptibility Trends Study, 1998 to 1999). Antimicrob. Agents Chemother 46(10), 3268-3272 (2002).
69. Singh J, Burr B, Stringham D et al. Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics. Paediatr. Drugs 3(10), 733-761 (2001).
70. Savani DV, Perfect JR, Cobo LM et al. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob. Agents Chemother. 31(1), 6-10 (1987).
71. Schulman JA, Peyman GA, Dietlein J et al. Ocular toxicity of experimental intravitreal itraconazole. Int. Ophthalmol. 15(1), 21-24 (1991).
72. Yoshizumi MO, Banihashemi AR. Experimental intravitreal ketoconazole in DMSO. Retina 8(3), 210-215 (1988).
73. Shahsavari M, Peyman GA, Niesman MR. Retinal toxicity and in vitro efficacy study of cilofungin (LY121019). Ophthalmic. Surg. 21(10), 726-728 (1990).
74. Dunlap WA, Karacorlu M, Peyman GA et al. Retinal toxicity of intravitreally injected faeriefungin. Ophthalmic. Surg. 25(5), 303-306 (1994).
75. Samly N, D'Amico DJ. Endogenous fungal endophthalmitis. Int. Ophthalmol, Clin. 36, 147-162 (1996).
76. Baldinger J, Doft BH, Burns SA et al. Retinal toxicity of amphotericin B in vittectomised versus non-vitrectomised eyes. Br. J. Ophthalmol. 70(9), 657-661 (1986).
77. Doft BH, Weiskopf J, Nilsson-Ehle I et al. Amphotericin clearance in vitrectomized versus nonvitrectomized eyes. Ophthalmology 92(11), 1601-1605 (1985).
78. Miyamoto H, Ogura Y, Hashizoe M, Kunou N, Honda Y, Ikada Y. Biodegradable scleral implant for intravitreal controlled release of fluconazole. Curr. Eye Res. 16, 930-935 (1997).
79. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 150(3), 101-115 (2001).
80. Sabo JA, Abdel-Rahman SM. Voriconazole: a new triazole antifungal. Ann. Pharmacother. 34(9), 1032-1043 (2000).
81. Hariprasad SM, Mieler WF, Holz ER et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch. Ophthalmol. 122(1), 42-47 (2004).
82. Lazarus HM, Blumer JL, Yanovich S et al. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J. Clin. Pharmacol. 42(4), 395-402 (2002).
83. Gao H, Pennesi ME, Shah K et al. Intravitreal voriconazole: an electroretinographic and histopathologic study. Arch. Ophthalmol. 122(11), 1687-1692 (2004).
84. Durand ML, Kim IK, D'Amico DJ et al. Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin. Am. J. Ophthalmol. 140(3), 552-554 (2005).
85. Kramer M, Kramer MR, Blau H, Bishara J, Axer-Siegel R, Weinberger D. Intravitreal voriconazole for the treatment of endogenous Aspergillus endopthalmitis. Ophthalmology 113(7), 1184-1186 (2006).
86. Nehemy MB, Vasconcelos-Santos DV, Torqueti-Costa L et al. Chronic endophthalmitis due to verticillium species after cataract surgery treated (or managed) with pars plana vitrectomy and oral and in travitreal voriconazole. Retina 26(2), 225-227 (2006).
87. Gupta AK, Tomas E. New antifungal agents. Dermatol. Clin. 21(3), 565-576 (2003).
88. Dodds Ashley ES, Alexander BD. Posaconazole. Drugs Today (Barc.) 41(6), 393-400 (2005).
89. Cuenca-Estrella M, Gomez-Lopez A, Mellado E et al. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob. Agents Chemother. 50(3), 917-921 (2006).
90. Sponsel WE, Graybill JR, Nevarez HL et al. Ocular and systemic posaconazole(SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis. Br. J. Ophthalmol. 86(7), 829-830 (2002).
91. Bachmann SP, Patterson TF, Lopez-Ribot JL. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J. Clin. Microbiol. 40, 2228-2230 (2002).
92. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347(25), 2020-2029 (2002).
93. Petraitis V, Petraitiene R, Groll AH et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently nentropenic rabbits. Antimicrob. Agents Chemotber. 46(6), 1857-1869 (2002).
94. Vazquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin. Infect. Dis. 43(2), 215-222 (2006).
95. Coats ML, Peyman GA. Intravitreal corricosteroids in the treatment of exogenous fungal endophthalmitis. Retina 12(1), 46-51 (1992).
96. Majji AB, Jalali S, Das T et al. Role of intravitreal dexamethasone in exogenous fungal endophthalmitis. Eye 13(Pt 5), 660-665 (1999).
97. Diamond RD. Inhibition of monocytemediated damage to fungal hyphae by steroid hormones. J. Infect. Dis. 147(1), 160 (1983).
98. Smiddy WE. Treatment outcomes of endogenous fungal endophthalmitis. Curr. Opin. Ophthalmol. 9(3), 66-70 (1998).
99. Recchia FM, Shah GK, Eagle RC, Sivalingam A, Fischer DH. Visual and anatomical outcome following submacular surgery for choroidal neovascularization secondary to Candida endophthalmitis. Retina 22, 323-329 (2002).
100. Jampol LM, Sung J, Walker JD et al. Choroidal neovascularization secondary to Candida albicans chorioretinitis. Am. J. Ophthalmol. 121, 643-649 (1996).
101. Gupta A, Gupta V, Dogra MR et al. Fungal endophthalmitis after a single intravenous administration of presumably contaminated dextrose infusion fluid. Retina 20(3), 262-268 (2000).
102. Voss A, le Noble JL, Verduyn Lunel FM et al. Candidemia in intensive care unit patients: risk factors for mortality. Infection 25(1), 8-11 (1997).
103. Betts R, Glasmacher A, Maertens J et al. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer 106, 466-473 (2006).